Literature DB >> 22957303

High levels of Hdmx promote cell growth in a subset of uveal melanomas.

Job de Lange, Amina Fas Teunisse, Matty Verlaan-de Vries, Kirsten Lodder, Suzanne Lam, Gregorius Pm Luyten, Federico Bernal, Martine J Jager, Aart G Jochemsen.   

Abstract

The p53 tumor suppressor pathway is inactivated in cancer either via direct mutation or via deregulation of upstream regulators or downstream effectors. P53 mutations are rare in uveal melanoma. Here we investigated the role of the p53 inhibitor Hdmx in uveal melanoma. We found Hdmx over-expression in a subset of uveal melanoma cell lines and fresh-frozen tumor samples. Hdmx depletion resulted in cell-line dependent growth inhibition, apparently correlating with differential Hdm2 levels. Surprisingly, p53 knockdown hardly rescued cell cycle arrest and apoptosis induction upon Hdmx knockdown, whereas it effectively prevented growth suppression induced by the potent p53 activator Nutlin-3. In addition, two compounds inhibiting Hdmx function or expression, SAH-p53-8 and XI-011, also elicited a growth inhibitory effect in a partly p53-independent manner. These findings suggest a novel, growth-promoting function of Hdmx that does not rely on its ability to inhibit p53. We provide evidence for a contribution of p27 protein induction to the observed p53-independent G1 arrest in response to Hdmx knockdown. In conclusion, our study establishes the importance of Hdmx as an oncogene in a subset of uveal melanomas and widens the spectrum of its function beyond p53 inhibition.

Entities:  

Keywords:  Hdmx; Nutlin-3; SAH-p53-8; Uveal melanoma; XI-011; p27; p53; retinoblastoma

Year:  2012        PMID: 22957303      PMCID: PMC3433101     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  66 in total

Review 1.  Ubiquitin ligases: cell-cycle control and cancer.

Authors:  Keiichi I Nakayama; Keiko Nakayama
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

2.  Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.

Authors:  Chiharu Uchida; Seiichi Miwa; Kyoko Kitagawa; Takayuki Hattori; Tomoyasu Isobe; Sunao Otani; Toshiaki Oda; Haruhiko Sugimura; Takehiko Kamijo; Keizou Ookawa; Hideyo Yasuda; Masatoshi Kitagawa
Journal:  EMBO J       Date:  2004-12-02       Impact factor: 11.598

Review 3.  Mdmx as an essential regulator of p53 activity.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Biochem Biophys Res Commun       Date:  2005-06-10       Impact factor: 3.575

4.  MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.

Authors:  Patima Sdek; Haoqiang Ying; Donny L F Chang; Wei Qiu; Hongwu Zheng; Robert Touitou; Martin J Allday; Zhi-Xiong Jim Xiao
Journal:  Mol Cell       Date:  2005-12-09       Impact factor: 17.970

5.  Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.

Authors:  Young Sun; Binh N Tran; Lori A Worley; Rachel B Delston; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-05       Impact factor: 4.799

6.  Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment.

Authors:  Haochuan Li; Jerry Y Niederkorn; Sudha Neelam; Hassan Alizadeh
Journal:  Exp Eye Res       Date:  2006-04-11       Impact factor: 3.467

7.  Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.

Authors:  Davide Danovi; Erik Meulmeester; Diego Pasini; Domenico Migliorini; Maria Capra; Ruth Frenk; Petra de Graaf; Sarah Francoz; Patrizia Gasparini; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Aart G Jochemsen; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

8.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

9.  Absence of BRAF and NRAS mutations in uveal melanoma.

Authors:  Frank Cruz; Brian P Rubin; David Wilson; Ajia Town; Arin Schroeder; Andrea Haley; Troy Bainbridge; Michael C Heinrich; Christopher L Corless
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Lack of BRAF mutations in uveal melanoma.

Authors:  Donata Rimoldi; Suzanne Salvi; Danielle Liénard; Ferdy J Lejeune; Daniel Speiser; Leonidas Zografos; Jean-Charles Cerottini
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  9 in total

1.  MDMX under stress: the MDMX-MDM2 complex as stress signals hub.

Authors:  Anna de Polo; Varunika Vivekanandan; John B Little; Zhi-Min Yuan
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

2.  Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

Authors:  Michael Dewaele; Tommaso Tabaglio; Karen Willekens; Marco Bezzi; Shun Xie Teo; Diana H P Low; Cheryl M Koh; Florian Rambow; Mark Fiers; Aljosja Rogiers; Enrico Radaelli; Muthafar Al-Haddawi; Soo Yong Tan; Els Hermans; Frederic Amant; Hualong Yan; Manikandan Lakshmanan; Ratnacaram Chandrahas Koumar; Soon Thye Lim; Frederick A Derheimer; Robert M Campbell; Zahid Bonday; Vinay Tergaonkar; Mark Shackleton; Christine Blattner; Jean-Christophe Marine; Ernesto Guccione
Journal:  J Clin Invest       Date:  2015-11-23       Impact factor: 14.808

3.  Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.

Authors:  Goutam Karan; Huaiyu Wang; Amit Chakrabarti; Sukanya Karan; Zhigang Liu; Zhiqiang Xia; Mahesh Gundluru; Stephen Moreton; Yogen Saunthararajah; Mark W Jackson; Mukesh K Agarwal; David N Wald
Journal:  Mol Cancer Ther       Date:  2016-02-16       Impact factor: 6.261

Review 4.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 5.  The role of MDM2 and MDM4 in breast cancer development and prevention.

Authors:  Sue Haupt; Reshma Vijayakumaran; Panimaya Jeffreena Miranda; Andrew Burgess; Elgene Lim; Ygal Haupt
Journal:  J Mol Cell Biol       Date:  2017-02-01       Impact factor: 6.216

6.  Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

Authors:  R C Heijkants; M Nieveen; K C 't Hart; A F A S Teunisse; A G Jochemsen
Journal:  Oncogenesis       Date:  2018-03-29       Impact factor: 7.485

7.  Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Authors:  Javier Octavio Mejía-Hernández; Dinesh Raghu; Franco Caramia; Nicholas Clemons; Kenji Fujihara; Thomas Riseborough; Amina Teunisse; Aart G Jochemsen; Lars Abrahmsén; Giovanni Blandino; Andrea Russo; Cristina Gamell; Stephen B Fox; Catherine Mitchell; Elena A Takano; David Byrne; Panimaya Jeffreena Miranda; Reem Saleh; Heather Thorne; Shahneen Sandhu; Scott G Williams; Simon P Keam; Ygal Haupt; Sue Haupt
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

8.  Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

Authors:  Guillaume Carita; Estelle Frisch-Dit-Leitz; Ahmed Dahmani; Chloé Raymondie; Nathalie Cassoux; Sophie Piperno-Neumann; Fariba Némati; Cécile Laurent; Leanne De Koning; Ensar Halilovic; Sebastien Jeay; Andrew Wylie; Caroline Emery; Sergio Roman-Roman; Marie Schoumacher; Didier Decaudin
Journal:  Oncotarget       Date:  2016-06-07

Review 9.  The long and the short of it: the MDM4 tail so far.

Authors:  Sue Haupt; Javier Octavio Mejía-Hernández; Reshma Vijayakumaran; Simon P Keam; Ygal Haupt
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.